Antibody-drug conjugates in clinical development in endometrial cancer
| Target | Name | Payload | Drug-to-antibody ratio | Linker | Development stage in endometrial cancer |
| HER2 | Trastuzumab deruxtecan (DS-8201a) | Topoisomerase I inhibitor (deruxtecan) | 8 | Cleavable (protease-sensitive) | Phase II FDA accelerated approval |
| HER2 | DB-1303 (BNT323) | Topoisomerase I inhibitor (P1003) | 8 | Cleavable (protease-sensitive) | Phase I/IIA |
| HER2 | Trastuzumab duocarmazine (SYD985) | DNA alkylating agent (duocarmazine) | 2.8 | Cleavable (protease-sensitive) | Phase II |
| HER2 | Disitamab vedotin (RC48) | Anti-microtubule agent (monomethyl auristatin E) | 4 | Cleavable (protease-sensitive) | Phase II |
| FRα | Mirvetuximab soravtansine (IMGN853) | Anti-microtubule agent (DM4) | 3.5 | Cleavable (glutathione-sensitive) | Phase II |
| FRα | Farletuzumab ecteribulin (MORAb-202) | Anti-microtubule agent (eribulin mesylate) | 4 | Cleavable (protease-sensitive) | Phase I/II |
| FRα | Luveltamab tazevibulin (SΤRO-002, SP8193) | Anti-microtubule agent (SC209) | 4 | Cleavable (protease-sensitive) | Phase I/IIA |
| FRα | PRO1184 | Topoisomerase I inhibitor (exatecan) | 8 | Cleavable (protease-sensitive) | Phase I/II |
| FRα | AMT-151 | Undisclosed | Undisclosed | Undisclosed | Phase I |
| FRα | IMGN151 | Anti-microtubule agent (DM21) | 3.5 | Cleavable (protease-sensitive) | Phase I |
| TROP2 | Sacituzumb govitecan (IMMU-132, hRS7-SN-38) | Topoisomerase I inhibitor (SN38) | 7.6 | Cleavable (pH-sensitive) | Phase II |
| TROP2 | Datopotamab deruxtecan (DS-1062) | Topoisomerase I inhibitor (deruxtecan) | 4 | Cleavable (protease-sensitive) | Phase II |
| TROP2 | Sacituzumab tirumotecan (MK-2870, SKB264) | Topoisomerase I inhibitor (tirumotecan) | 7.4 | Cleavable (pH-sensitive) | Phase III |
| TROP2 | LCB84 | Anti-microtubule agent (monomethyl auristatin E) | 4 | Cleavable (β-glucuronidase-sensitive) | Phase I/II |
| B7-H4 | SGN-B7H4V | Anti-microtubule agent (monomethyl auristatin E) | 4 | Cleavable (protease-sensitive) | Phase I |
| B7-H4 | HS-20089 | Topoisomerase I inhibitor (undisclosed) | 6 | Cleavable (protease-sensitive) | Phase II |
| B7-H4 | XMT-1660 | Anti-microtubule agent (auristatin F-HPA) | 6 | Cleavable | Phase I |
| B7-H4 | AZD8205 | Topoisomerase I inhibitor (AZ14170133) | 8 | Cleavable (protease-sensitive) | Phase I/IIA |
| TF | Tisotumab vedotin | Anti-microtubule agent (monomethyl auristatin E) | 4 | Cleavable (protease-sensitive) | Phase II |
| TF | XB002 | Anti-microtubule agent (monomethyl auristatin E) | 3.3 | Cleavable (protease-sensitive) | Phase I |
| AXL | Enapotamab vedotin (HuMax-AXL-ADC, AXL-107-MMAE) | Anti-microtubule agent (monomethyl auristatin E) | 4 | Cleavable (protease-sensitive) | Phase I/II |
| Claudin 6 | TORL-1–23 | Anti-microtubule agent (monomethyl auristatin E) | Undisclosed | Cleavable (protease-sensitive) | Phase I |
| B7-H3 | Ifinatamab veruxtecan (DS-7300a, MABX-9001a) | Topoisomerase I inhibitor (deruxtecan) | 4 | Cleavable (protease-sensitive) | Phase I |
FDA, Food and Drug Administration; FRα, folate receptor alpha; HER2, human epidermal growth factor receptor 2; TF, tissue factor; TROP2, trophoblast cell-surface antigen-2.